U.S. states reject $18 billion proposal to settle opioid lawsuits,
discussions ongoing: sources
Send a link to a friend
[February 15, 2020]
By Tom Hals and Diane Bartz
(Reuters) - Twenty one states have rejected
an $18 billion settlement proposal from three major U.S. drug
distributors to resolve lawsuits over their alleged role in the opioid
crisis, but discussion are still active, according to three sources
familiar with the matter.
More than 2,500 lawsuits have been brought nationwide by states, local
and tribal governments over the toll the opioid crisis has taken on
their communities.
The Wall Street Journal reported on Friday that the states objected to a
settlement offer sent to the companies' law firms earlier this week, and
were pushing for a larger payment.
"We're far along in the process of talks and still negotiating," said
Sarah Lovenheim, spokeswoman for California Attorney General Xavier
Becerra. "For anyone to suggest otherwise would be inaccurate."
Sources with three other state attorneys general told Reuters the
parties are in active discussions, adding the proposal is not dead but
requires wider support.
The states want the companies - AmerisourceBergen Corp, McKesson Corp
and Cardinal Health Inc - to pay between $22 billion and $32 billion,
the WSJ reported https://on.wsj.com/37kSRkA, citing a person familiar
with a matter.
States also want the money faster than the companies' proposal, which
was for $18 billion over 18 years, one of the sources told Reuters. The
state attorneys general believe distributors can pay more than $18
billion dollars over a shorter period of time, the person said.
Some 400,000 U.S. overdose deaths between 1997 and 2017 were linked to
opioids, according to government data.
The lawsuits accuse drugmakers of deceptively marketing opioids in ways
that downplayed their risks, and drug distributors of failing to detect
and halt suspicious orders. The companies have denied any wrongdoing.
[to top of second column]
|
Shares of the three distributors, which together handle about 85% of
the U.S. prescription drug market, were down less than 1%.
The $18 billion proposal would only settle allegations with the
distributors and does not includes claims against pharmacies like
Walgreens Boots Alliance Inc and drugmakers including Teva
Pharmaceutical Industries.
A trial is scheduled to begin on March 20 in which the state of New
York and the counties of Suffolk and Nassau are suing drug
distributors, drugmakers such as Johnson & Johnson and pharmacy
chains including CVS Health Corp.
The $18 billion settlement was proposed on the eve of the last major
opioid trial in Cleveland in October. The New York trial date could
help push the parties to a deal.
McKesson said it is focused on finalizing a global settlement that
would provide billions of dollars in immediate funding and relief to
states and local communities, a company spokesman said in an emailed
statement.
"We are committed to being part of the solution, but are also
prepared to defend ourselves vigorously if the litigation
progresses," he added.
A Cardinal Health spokesperson said the company continues to work
toward a nationwide settlement.
AmerisourceBergen did not immediately respond to a request for
comment.
The rejection letter was signed by attorneys general for 21 states
as well as Puerto Rico and the District of Columbia, according to
the WSJ report.
(Reporting by Tom Hals in Delaware, Diane Bartz in Washington and
Saumya Sibi Joseph in Bengaluru; Writing by Michael Erman in New
York; Editing by Shinjini Ganguli and Bill Berkrot)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |